Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 2/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.39 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.37 |
| ▸ | KRAS | P01116 | 1/20 | 0.33 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1370258 | 0.83 | ESR2 (0.39) | ESR2ALDH1A1HPGDCYP2A6PTPN5 | |
| SCHEMBL27863227 | 0.81 | ESR2 (0.37) | ESR2CYP2A6PTPN5KRASSOS1 | |
| SCHEMBL29268621 | 0.74 | ESR2 (0.46) | ESR2MEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL28168138 | 0.74 | HPGD (0.53) | ESR2MEN1ALDH1A1MAPTHPGD | |
| SCHEMBL2408832 | 0.74 | HPGD (0.48) | ESR2MEN1ALDH1A1MAPTHPGD | |
| SCHEMBL8791236 | 0.74 | ALDH1A1 (0.46) | ESR2ALDH1A1HPGDKRASSOS1 | |
| SCHEMBL27711651 | 0.71 | ESR2 (0.44) | ESR2PTPN5FFAR1AKR1B1CYP3A4 | |
| SCHEMBL8572801 | 0.71 | MEN1 (0.70) | MEN1ALDH1A1MAPTHPGDKMT2A | |
| SCHEMBL7667378 | 0.69 | ESR2 (0.53) | ESR2ALDH1A1MAPTDPP4PTPN5 | |
| SCHEMBL8576605 | 0.69 | DPP4 (0.69) | ESR2MEN1ALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115136-B2 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-25 | — | — | US | disclosed |
| US-8921379-B2 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-30 | — | — | US | disclosed |
| CN-102369205-B | fused ring compound and use thereof | TAKEDA PHARMACEUTICAL CO.,LTD. (JP) | 2014-10-29 | — | — | CN | disclosed |
| CN-103788097-A | Fused ring compound and application thereof | TAKEDA PHARMACEUTICAL | 2014-05-14 | — | — | CN | disclosed |
| US-20140046056-A1 | FUSED RING COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-02-13 | — | — | US | disclosed |
| US-8592431-B2 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-26 | — | — | US | disclosed |
| EP-2384327-B1 | FUSED RING COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2013-07-31 | — | — | EP | disclosed |
| US-8283353-B2 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-09 | — | — | US | disclosed |
| CN-102369205-A | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL | 2012-03-07 | — | — | CN | disclosed |
| US-20110294832-A1 | FUSED RING COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-12-01 | — | — | US | disclosed |
| US-20110288087-A1 | FUSED RING COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-11-24 | — | — | US | disclosed |
| EP-2384327-A1 | FUSED RING COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-20100197683-A1 | FUSED RING COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-08-05 | — | — | US | disclosed |
| WO-2010087515-A1 | FUSED RING COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140046056-A1 | FUSED RING COMPOUND AND USE THEREOF | PPARA, PPARG, AGTR2 | ESR2 147/4885MEN1 4648/4885ALDH1A1 1050/4885 |
| US-20110288087-A1 | FUSED RING COMPOUND AND USE THEREOF | PPARA, PPARG, AGTR2 | ESR2 147/4885MEN1 4648/4885ALDH1A1 1050/4885 |
| US-20110294832-A1 | FUSED RING COMPOUND AND USE THEREOF | PPARA, PPARG, AGTR2 | ESR2 147/4885MEN1 4648/4885ALDH1A1 1050/4885 |
| US-20100197683-A1 | FUSED RING COMPOUND AND USE THEREOF | PPARA, PPARG, AGTR2 | ESR2 147/4885MEN1 4648/4885ALDH1A1 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.